
Daily Derm Times: February 14, 2025
Key Takeaways
- Dermatologists should be aware of potential 2025 tax law changes, including expiring TCJA provisions and new deduction policies.
- Bimekizumab shows long-term efficacy in hidradenitis suppurativa, with over 85% of patients maintaining response and reduced draining tunnels.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our
Potential 2025 Tax Law Changes: What Dermatologists Should Know
Key 2025 tax law changes for dermatologists include expiring TCJA provisions, potential rate adjustments, and new deduction policies under Trump.
How Well Revolution Combines In-Person Care with Telehealth
Michael Rubio, PA-C talks with Renata Block, MMS, PA-C, about his virtual care platform and how it can expand access to care.
New Data on Bimekizumab’s Long-term HS Efficacy
Bimekizumab demonstrated long-term effectiveness in patients with HS, with over 85% maintaining response and reduced draining tunnels.
Tailoring Atopic Dermatitis Treatment to Meet Patient Needs
Adelaide A. Hebert, MD, FAAD, stressed the importance of educating patients, setting realistic expectations, and ensuring they adhere to AD treatment plans.
Nektar's Jonathan Zalevsky, PhD, Dives Into Rezpegaldesleukin Fast Track Designation for Atopic Dermatitis
Zalevsky shares insights into the implications of the designation and what it may mean for Rezpeg's development timeline.
Bridging Dermatology and Psychological Support
A global review found that skin condition advocacy groups offer diverse mental health resources, but accessibility gaps persist worldwide.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















